REDUCE follow up study of dutasteride for prostate cancer risk reduction

Source: J Urology Area: News The original 4 year REDUCE (REduction by DUtasteride of prostate Cancer Events) trial evaluated dutasteride (0.5mg daily) for prostate cancer risk reduction in men at increased risk for prostate cancer (older age, increased PSA levels) found that dutasteride reduced the relative risk of biopsy detectable prostate cancer by 22.8% (95% CI 15.2-29.8) compared with placebo.   In the current REDUCE Follow-Up Study, 2,751 of the original participants were followed up for an additional two years during which time no drugs were provided and all biopsies were performed for cause. The primary end point was the occurrence of new biopsy detectable prostate cancers.   The study demonstrated that after an additional two years, few new prostate cancers were detected in either group (14 cases in dutasteride group vs 7 in the placebo group). None of these cancers were high grade cancers (Gleason score 8-10) and no new safety issues were identified during the study.   ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news